-
Mashup Score: 6Combination Casirivimab and Imdevimab and Development of Symptomatic COVID-19 in SARS-CoV-2 Infection - 2 year(s) ago
This randomized trial assesses the effect of a single dose of subcutaneous casirivimab and imdevimab antibody combination vs placebo on 28-day progression to symptomatic COVID-19 among asymptomatic SARS-CoV-2 reverse transcriptase–quantitative polymerase chain reaction–positive individuals living…
Source: jamanetwork.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 16
Casirivimab/imdevimab protected uninfected contacts from COVID-19 and reduced symptomatic infections in trials before Omicron emerged.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
#Casirivimab and #imdevimab #monoclonal antibody combination prevented #COVID19 symptoms in trials before emergence of #Omicron https://t.co/IwB5rWJwOs
-
-
Mashup Score: 8Combination Casirivimab and Imdevimab and Development of Symptomatic COVID-19 in SARS-CoV-2 Infection - 2 year(s) ago
This randomized trial assesses the effect of a single dose of subcutaneous casirivimab and imdevimab antibody combination vs placebo on 28-day progression to symptomatic COVID-19 among asymptomatic SARS-CoV-2 reverse transcriptase–quantitative polymerase chain reaction–positive individuals living…
Source: jamanetwork.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Study found treatment with subcutaneous #casirivimab and #imdevimab antibody combination compared with placebo significantly reduced the incidence of symptomatic #COVID19 among recently exposed, asymptomatic individuals. https://t.co/9udWGUOsD9 https://t.co/V6wOI2fNqW
-
-
Mashup Score: 16Combination Casirivimab and Imdevimab and Development of Symptomatic COVID-19 in SARS-CoV-2 Infection - 2 year(s) ago
This randomized trial assesses the effect of a single dose of subcutaneous casirivimab and imdevimab antibody combination vs placebo on 28-day progression to symptomatic COVID-19 among asymptomatic SARS-CoV-2 reverse transcriptase–quantitative polymerase chain reaction–positive individuals living…
Source: jamanetwork.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Study found treatment with subcutaneous #casirivimab and #imdevimab antibody combination compared with placebo significantly reduced the incidence of symptomatic #COVID19 among recently exposed, asymptomatic individuals. https://t.co/T7GuYt8gv8 https://t.co/lwl0usw6KN
-
-
Mashup Score: 5Combination Casirivimab and Imdevimab and Development of Symptomatic COVID-19 in SARS-CoV-2 Infection - 2 year(s) ago
This randomized trial assesses the effect of a single dose of subcutaneous casirivimab and imdevimab antibody combination vs placebo on 28-day progression to symptomatic COVID-19 among asymptomatic SARS-CoV-2 reverse transcriptase–quantitative polymerase chain reaction–positive individuals living…
Source: jamanetwork.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Study found treatment with subcutaneous #casirivimab and #imdevimab antibody combination compared with placebo significantly reduced the incidence of symptomatic #COVID19 among recently exposed, asymptomatic individuals. https://t.co/USHxSRjsI5
-
-
Mashup Score: 221
On September 17, Mayra Arana made the phone call she says saved her life.
Source: CNNCategories: Infectious Disease, Latest HeadlinesTweet-
RT @RazonableMD This news piece comes at a time when the Monoclonal Antibody Treatment MATRx Program surpasses 14,000 patients with covid-19 infused with these lifesaving antibodies - CNN #casirivimab #bamlanivimab #sotrovimab https://t.co/qYBdCQwy2O
-
-
Mashup Score: 27
On September 17, Mayra Arana made the phone call she says saved her life.
Source: CNNCategories: Healthcare Professionals, Latest HeadlinesTweet-
Doctors are often unaware of the only treatment for early Covid-19 monoclonal antibodies - which reduce risk of #covid hospitalizations/death by 70% to 85% but @mayoclinic used EHR + education to proactively screen and reach out to patients - via @CNN https://t.co/24v6UFgipQ
-
Monoclonal antibodies as treatment for early Covid-19 - CNN @MayoClinicINFD #casirivimab #bamlanivimab #sotrovimab https://t.co/u47NnzVdpf
-
-
Mashup Score: 6
Among high-risk patients with mild to moderate COVID-19, casirivimab–imdevimab treatment was associated with a significantly lower rate of hospitalization.
Source: EClinicalMedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
A new retrospective cohort study analysed the outcomes of #casirivimab–#imdevimab treatment in patients with mild to moderate #COVID19 @RazonableMD @MayoClinicINFD @Ravi_Ganesh_MD Read more: https://t.co/W5j1M11tYn https://t.co/lbbFBzCRfa
-
-
Mashup Score: 0
Regeneron’s monoclonal antibodies, casirivimab and imdevimab (REGEN-COV), reduced risk of death by 20% in patients hospitalized with COVID-19 who had not mounted their own immune response.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
The #Regeneron #monoclonal #antibodies #casirivimab and #imdevimab (REGEN-COV) reduced risk of death by 20% in patients hospitalized with #COVID19 who had not mounted their own immune response. Company is seeking expansion of #FDA EUA https://t.co/5yq5kGUPpe
-
-
Mashup Score: 0Monoclonal antibody cocktail cut COVID-19 hospitalization, death by 70% in outpatient setting - 3 year(s) ago
A cocktail of two monoclonal antibodies — casirivimab and imdevimab — significantly reduced the risk for hospitalization or death in nonhospitalized patients with COVID-19, according to results of a phase 3 pivotal trial.Casirivimab with imdevimab (REGEN-COV, Regenerson) also shortened symptom duration and reduced viral load, researchers reported during a breaking news session at the
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet-
Presented at #ATS2021: Monoclonal antibody cocktail (REGEN-COV) of #casirivimab plus #imdevimab significantly hospitalization, death, symptom duration and viral load in non-hospitalized patients with #COVID19 @InfectDisNews https://t.co/2FkNau6qQK
-
Study found treatment with subcutaneous #casirivimab and #imdevimab antibody combination compared with placebo significantly reduced the incidence of symptomatic #COVID19 among recently exposed, asymptomatic individuals. https://t.co/7Mk6V2ZMQc